LATEST
Corruption Files
Airport arrest scene
Medical Fraud

Owner of Oregon Clinical Laboratory Charged in $46 Million Medicare Fraud

By

Ahsan Qureshi, 47, a Pakistani national who owned and operated Portland-based Northwest Diagnostic Labs, was arrested Sunday at Los Angeles International Airport while attempting to board a one-way flight to Dubai.

A federal indictment unsealed Monday charges Qureshi with 14 counts of healthcare fraud, money laundering, and identity theft. Prosecutors allege that between 2021 and 2025, Qureshi billed Medicare approximately $46 million for diagnostic tests β€” including genetic cancer screening and cardiovascular panels β€” that were never performed.

The scheme allegedly involved paying telemedicine doctors $200 per signed order, often using stolen patient identities. Many of the 'patients' were unaware their names were being used. Qureshi used the proceeds to purchase real estate in Oregon, Arizona, and Pakistan, as well as a 2023 Ferrari.

Fugitive apprehension efforts

The FBI had been monitoring Qureshi for three weeks before his arrest. He had liquidated several assets and obtained a Pakistani passport under a different name. 'This was a sophisticated effort to flee justice,' said FBI Special Agent in Charge Kieran Ramsey.

If convicted, Qureshi faces up to 20 years per fraud count and 10 years per money laundering count. A detention hearing is scheduled for Thursday.

This was a sophisticated effort to flee justice. But we were watching, and he will now face the consequences of defrauding American taxpayers.

β€” FBI Special Agent in Charge Kieran Ramsey

The government has frozen approximately $12 million in Qureshi's U.S. bank accounts and seized the Ferrari. His Oregon medical license has been summarily suspended.

Mirror Standard β€” Investigative Journalism
Ruth Anselmi β€” author photo
About Author

Ruth trained as a pharmacist and then spent a decade watching the gap between clinical trial data and real-world outcomes grow wider every year. She left the industry after a whistleblower case she had quietly supported was settled out of court under a non-disclosure agreement. Her reporting cuts through press releases and FDA approval language to ask the questions that should have been asked before the drug reached the shelf.

SubstackMedium

Related posts